latest update:
[TrialBase DB]

trial summary · NCT04861077

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study

Trial record from the TrialBase DB dataset, status RECRUITING, condition Triple Negative Breast Cancer, sponsored by University of Alabama at Birmingham. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT04861077phase EARLY_PHASE1enrollment 20start 2027-06

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This clinical study will investigate the utility of Fludeoxyglucose (18F) fluoromisonidazole (FMISO), in patients diagnosed with triple negative breast cancer (stage II-IV disease), to monitor and predict the effect of immunotherapy. This is a parallel imaging study to current treatment strategies and no clinical decisions or outcomes will be based on the imaging. If promising, this data will be used to design larger trials. A total of 20 patients will be recruited for this study. This trial will not designate the participant's treatment plan; they will be eligible based on their treatment plan designated from their oncologist.

Source record: https://clinicaltrials.gov/study/NCT04861077

Facts

registry idNCT04861077
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phaseEARLY_PHASE1
study typeINTERVENTIONAL
lead conditionTriple Negative Breast Cancer
sponsorUniversity of Alabama at Birmingham
sponsor classOTHER
enrollment20
start date2027-06
primary completion2030-08
completion2030-08
results postednot reported

Conditions

  • Triple Negative Breast Cancer

Interventions

  • [18F]FMISO-PET with contrast-enhanced MRI

Countries

  • United States

Intervention types: DRUG

Work with this record